Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | TLR4 | O00206 | 2/20 | 0.30 |
| ▸ | CD14 | P08571 | 2/20 | 0.30 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046758 | 0.80 | USP2 (0.37) | SMN1; SMN2HSD17B10 | |
| SCHEMBL16501729 | 0.79 | ATM (0.36) | TLR4CD14LY96 | |
| SCHEMBL16501701 | 0.78 | CYP2C19 (0.36) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A | |
| SCHEMBL12958642 | 0.76 | CYP2C19 (0.55) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A | |
| SCHEMBL10046770 | 0.75 | CYP2C19 (0.35) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A | |
| SCHEMBL10046755 | 0.74 | HTR1D (0.39) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A | |
| SCHEMBL70807 | 0.74 | CYP2C19 (0.53) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A | |
| SCHEMBL10046757 | 0.73 | MAPT (0.39) | SMN1; SMN2HSD17B10 | |
| SCHEMBL14213242 | 0.73 | CYP2C19 (0.33) | CYP2C19CYP2C9CYP2D6CYP1A2SCN2A | |
| SCHEMBL10046743 | 0.70 | CYP2C19 (0.49) | CYP2C19CYP2C9CYP2D6CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | CYP2C19 3478/4885CYP2C9 3820/4885CYP2D6 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.